Market Research Report
Plant-based Vaccines Market - Size, Share, Outlook, and Opportunity Analysis, 2018 - 2026
|Published by||Coherent Market Insights||Product code||769555|
|Published||Content info||128 Pages
Delivery time: 2-3 business days
|Plant-based Vaccines Market - Size, Share, Outlook, and Opportunity Analysis, 2018 - 2026|
|Published: December 31, 2018||Content info: 128 Pages||
Plants are a cost-effective, safe, and efficacious platform for large-scale production of vaccine in emerging economies and have the potential via oral administration to elicit a mucosal immune response. Key players in the market are focused on Research & Development (R&D) activities for development of plant-based vaccines for the treatment of infectious diseases. This is owing to the ability of plant-based vaccines to be mass produced, with higher efficiency, while maintaining lower cost compared to conventional vaccines.
Furthermore, increasing prevalence of infectious diseases is expected to drive growth of the plant-based vaccines market. For instance, according to World Health Organization (WHO) December 2017 estimate, a seasonal influenza may result in 290,000- 650,000 deaths each year owing to respiratory diseases alone.
Plants as a vaccine source have the ability to generate complex recombinant proteins with desired structures, while maintaining biological functions and offering greater immune-specificity. Plants can be used as potential delivery system for oral vaccines. These factors propel demand for plant-based vaccines. Moreover, successful completion of ongoing clinical trials studies in the future, is expected to offer lucrative opportunity to manufacturers thus, driving growth of the plant-based vaccines market. For instance, according to clinicalTrials: September 2015 update, clinical study evaluating a safety, tolerability and immunogenicity of a plant-made seasonal Quadrivalent VLP influenza vaccine in adults is currently in phase II clinical stage.
Higher efficiency of plant-based vaccines over conventional vaccines and R&D activities and clinical trials for the development plant-based are some of the factors expected to boost growth of the market. Plant-based vaccines against HIV have gained significant traction of researchers, since AIDS has evolved as an alarming health problem, which is increasing economic burden of African countries and several emerging economies. According to the The Joint United Nations Programme on HIV/AIDS (UNAIDS); in 2017, Eastern Europe, Central Asia, the Middle East and North Africa accounted for 95% of new HIV infections. Easy production, oral administration of plant-based vaccines, and absence of purification needs offer great advantage in designing plant-based viral vaccines.
Oral vaccines using plant-based formulations are considered as an alternative or may supplement for standard injection vaccines in the Hepatitis B (HBV) treatment, owing to low-cost production and easy vaccination. However, low efficiency and oral-tolerance are the main barrier in the production of plant-based anti-HBV vaccines. Moreover, according to a report published in the International Journal of Molecular Sciences, January 2013, in order to increase the efficiency of HBV antigen expression, intravenous injection of vaccine is required, as plant-produced purified HBV antigens are highly immunogenic when injected.
"*" marked represents similar segmentation in other categories in the respective section.